The gp120 protein in the HIV envelope initially makes contact with CD4, a protein receptor on the target cell surface, in order to infect cells. This first interaction with CD4 allows the viral protein gp120 to change its shape — facilitating the virus 'entry into the cell. There are currently two FDA-approved drugs that can block this process — Maraviroc and Enfuvirtide — and the same class (entry inhibitors) search for more drugs continue. The researchers investigated MF275's ability to prevent infection by various HIV strains. In some cases the medication effectively blocked entry. However, in others the drug has not only struggled to prevent entry, it has also increased the infection risk. Although this effect may be a backlash for drug growth, it points to possible new avenues for science. First, it reveals vulnerabilities which HIV can use to infect host cells which should be patched in future drug development rounds. Second, it illuminates the different ways in which HIV uses to invade cells, details that may help discover new forms of entry inhibitors or other ways of preventing HIV infection, such as antibodies. This review tells about the future scope of the new HIV infection inhibitory drugs invention which will help in treating and inhibiting the causing agents replication in the body. The People who are interested can send their article towards our journal for publication through this link link https://www.scholarscentral.org/submissions/hiv-aids-research.html.